

Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Jamp-Tobramycin 40 mg/ml Injection (DIN 02420287) manufactured by Jamp Pharma Corporation and Tobramycin USP 40 mg/ml Injection (DIN 02382814), manufactured by Mylan Pharmaceuticals ULC, Tobramycin 40 mg/ml Injection (DIN 02241210) manufactured by Sandoz Canada Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **May 3, 2017**, all claims for Tobramycin 40 mg/ml Injection (DIN 02241210), manufactured by Sandoz Canada Inc. will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product will be subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

Due to the unavailability of Jamp-Sodium Phosphate Effervescent Tablet (NPN 80047562) manufactured by Jamp Pharma Corporation, Phosphate-Novartis Effervescent Tablet (NPN 80027202) manufactured by Novartis Pharmaceuticals Canada Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **May 4, 2017**, all claims for Phosphate-Novartis Effervescent Tablet (NPN 80027202) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product will be subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

Due to the unavailability of Pamidronate Disodium 30 mg/10 ml Vial Injection (DIN 02244550) manufactured by Hospira Healthcare Corporation, Pamidronate Disodium 30 mg/10 ml Vial Injection (DIN 02246597) manufactured by Fresenius Kabi Canada, will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **May 16, 2017**, all claims for Pamidronate Disodium 30 mg/10 ml Vial Injection (DIN 02246597) manufactured by Fresenius Kabi Canada, will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product will be subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

... continued from previous page

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Ketorolac Tromethamine 30 mg/ml Injection (DIN 02239944) manufactured by Sandoz Canada Inc., Ketorolac Tromethamine 30 mg/ml Injection (DIN 02244947) manufactured by Fresenius Kabi Canada was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Sandoz Canada Inc. has advised Alberta Blue Cross that the shortage of Ketorolac Tromethamine 30 mg/ml Injection (DIN 02239944) has been resolved.

As a result, Ketorolac Tromethamine 30 mg/ml Injection (DIN 02244947) will no longer be considered a temporary benefit for the *ADBL* **after June 9, 2017**.

Due to the shortage of Teva-Fluvastatin 40 mg Capsule (DIN 02299232) manufactured by Teva Canada Limited, Sandoz Fluvastatin 40 mg Capsule (DIN 02400243) manufactured Sandoz Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Teva Canada Limited has advised Alberta Blue Cross that the shortage of Teva-Fluvastatin 40 mg Capsule (DIN 02299232) has been resolved.

As a result, Sandoz Fluvastatin 40 mg Capsule (DIN 02400243) will no longer be considered a temporary benefit for the *ADBL* **after June 19, 2017**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.689 2017/05

